Search results
21st.BIO unveils a new pilot plant facility to accelerate impact of biotech innovations globally
KFDX Wichita Falls· 2 hours agoCombining world-class industrially proven technology with fermentation capacity, 21st.BIO helps...
Zura Bio (NASDAQ:ZURA) Earns Overweight Rating from Analysts at Piper Sandler
ETF DAILY NEWS· 7 hours agoPiper Sandler initiated coverage on shares of Zura Bio (NASDAQ:ZURA – Free Report) in a report published on Friday, MarketBeat.com reports. The brokerage issued an overweight ...
Bio-Gate Reports Full Year 2023 Earnings
Simply Wall St. via Yahoo Finance· 1 day agoBio-Gate (FRA:BIG1) Full Year 2023 Results Key Financial Results Revenue: €7.48m (up 22% from FY 2022). Net loss: €1.62m (loss narrowed by 10% from FY...
Stockholm Exergi announces permanent carbon removal agreement with Microsoft, world's largest to...
FOX 59 Indianapolis· 3 hours agoStockholm Exergi today announced that it has signed a contract with Microsoft covering 3.33 million...
Yousif Capital Management LLC Acquires 51 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)
ETF DAILY NEWS· 1 day agoYousif Capital Management LLC increased its holdings in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO – Free Report) by 1.9% during the fourth quarter, ...
Earnings call: Bio-Techne sees growth in Q3 with strong market positioning
Investing.com· 4 days agoBio-Techne (NASDAQ: TECH ) Corporation ( NASDAQ : TECH) reported a 2% year-over-year organic revenue...
Bio-Techne Corporation (NASDAQ:TECH) Q3 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 4 days agoBio-Techne Corporation (NASDAQ:TECH) Q3 2024 Earnings Call Transcript May 1, 2024 Bio-Techne...
Gritstone bio Inc. (GRTS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Zacks via Yahoo Finance· 4 days agoGritstone bio (GRTS) possesses the right combination of the two key ingredients for a likely...
Brokerages Set Belite Bio, Inc (NASDAQ:BLTE) Target Price at $44.83
ETF DAILY NEWS· 1 day agoBelite Bio, Inc (NASDAQ:BLTE – Get Free Report) has been given an average recommendation of “Buy” by the seven analysts that are currently covering the firm, MarketBeat Ratings ...
Gossamer Bio reports positive phase 2 trial results for PAH treatment By Investing.com
Investing.com· 3 days agoGossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company, has announced the...